Triple agent immunosuppressive therapy in Vogt-Koyanagi-Harada syndrome

Ocular Immunology and Inflammation

Volumn 14, Issue 6, 2006, Pages 333-339

  Agarwal, Mamta ^a   Ganesh, Sudha K ^a   Biswas, Jyotirmay ^a  

^a MEDICAL RESEARCH FOUNDATION   (India)

Author keywords

Riple agent immunosuppression; VKH

Indexed keywords

AZATHIOPRINE; CYCLOPLEGIC AGENT; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISOLONE; STEROID;

ADULT; BIOMICROSCOPY; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; EYE FUNDUS; FEMALE; GLAUCOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MENSTRUAL IRREGULARITY; MOON FACE; OBESITY; OPHTHALMOSCOPY; OPPORTUNISTIC INFECTION; PHARYNGITIS; RECURRENCE RISK; REMISSION; RETROSPECTIVE STUDY; REVIEW; SINGLE DRUG DOSE; SLIT LAMP; STRIA; SUBCAPSULAR CATARACT; TREATMENT OUTCOME; VOGT KOYANAGI SYNDROME;

ADULT; AZATHIOPRINE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; FUNDUS OCULI; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; OPHTHALMOSCOPY; PREDNISOLONE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; UVEOMENINGOENCEPHALITIC SYNDROME;

EID: 33845631371     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.1080/09273940600976938     Document Type: Review

References (13)

1. Moorthy RS, Inomata H, Rao NA. Vogt Koyanagi Harada syndrome. Surv Ophthalmol. 1995;39:265-292.
2. Hemady R, Tauber J, Foster CS. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol. 1991;35:369-385.
3. Nussenblatt RB, Palestine AG,Chan CC. Cyclosporine A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol. 1983;96:275-282.
4. Wakatsuki Y, Kogure M, Takahshi Y, Oguro Y. Combination therapy with cyclosporine A and steroid in severe case of Vogt Koyanagi Harada's disease. Jpn J Ophthalmol. 1988;32:358-360.
5. Hooper PL, Kaplan HJ. Triple agent immunosuppression in serpiginous choroiditis. Ophthalmology. 1991;98(6):944-951.
6. Ganesh SK, Narayana KM, Biswas J. Peripapillary choroidal atrophy in sympathetic ophthalmia and management with triple-agent immunosuppression. Ocul Immunol Inflamm. 2003;11(1):61-65.
7. Rubsamen PE, Gass JD. Vogt-Koyanagi-Harada syndrome: clinical course, therapy, and long-term visual outcome. Arch Ophthalmol. 1991;109:682-687.
8. Andrasch RH, Burns RP. Immunosuppressive therapy in severe chronic uveitis. Arch Ophthal. 1978;96:247-251.
9. Mourad G et al. Triple agent immunosuppression (cyclosporine, azathioprine and low dose prednisolone) an effective regimen in first cadaver kidney transplantation. Transplant Proct. 1987;19:3672-3673.
10. Vitale AT, Rodriguez A, Foster S. Low dose cyclosporine A therapy in treating chronic, noninfectious uveitis. Ophthalmol. 1996;103:365-374.
11. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492-513.
12. Wider RL. Treatment of patients with rheumatoid arthritis refractory to standard therapy. JAMA. 1988;259:2446-2449.
13. Read RW, Holland GN, Rao NA, Tabbara KF, et al. Revised diagnostic criteria for Vogt Koyanagi Harada disease: report of an International Committee on Nomenclature. Am J Ophthalmol. 2001;131:647-652.